Verition Fund Management LLC Alkermes Plc. Transaction History

Verition Fund Management LLC

$17.4 Billion
Q3 2024

A detailed history of Verition Fund Management LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Verition Fund Management LLC holds 14,455 shares of ALKS stock, worth $416,014. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,455

Previous 8,592 68.24%

Holding current value

$416,014

Previous $207,000 95.17%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $134,907 - $167,388	5,863 Added 68.24%	14,455 $404,000
Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $4.58 Million - $5.38 Million	-197,379 Reduced 95.83%	8,592 $207,000
Q1 2024 May 14, 2024	BUY	$26.4 - $32.56 $5.24 Million - $6.46 Million	198,491 Added 2653.62%	205,971 $5.58 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $93,433 - $114,662	-3,998 Reduced 34.83%	7,480 $207,000
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $271,564 - $319,540	-9,995 Reduced 46.55%	11,478 $321,000
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $240,549 - $285,451	8,488 Added 65.37%	21,473 $672,000
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $793,696 - $910,038	-31,359 Reduced 70.72%	12,985 $366,000
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $1.16 Million - $1.39 Million	-53,044 Reduced 54.47%	44,344 $1.16 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $1.04 Million - $1.5 Million	47,162 Added 93.9%	97,388 $2.18 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $1.33 Million - $1.53 Million	50,226 New	50,226 $1.5 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $200,911 - $276,221	-8,597 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $355,317 - $475,838	-18,920 Reduced 68.76%	8,597 $211,000
Q1 2021 May 18, 2021	BUY	$18.21 - $23.2 $501,084 - $638,394	27,517 New	27,517 $514,000
Q1 2020 May 15, 2020	SELL	$13.06 - $21.24 $217,553 - $353,815	-16,658 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $1,400 - $1,760	81 Added 0.49%	16,658 $340,000
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $80,478 - $100,155	4,125 Added 33.13%	16,577 $323,000
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $267,344 - $464,833	12,452 New	12,452 $281,000
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $288,941 - $371,249	-10,174 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $116,258 - $185,622	4,161 Added 69.2%	10,174 $300,000
Q3 2018 Nov 15, 2018	SELL	$38.6 - $46.12 $41,109 - $49,117	-1,065 Reduced 15.05%	6,013 $255,000
Q2 2018 Aug 15, 2018	BUY	$40.56 - $51.36 $32,813 - $41,550	809 Added 12.9%	7,078 $291,000
Q1 2018 May 16, 2018	BUY	$53.61 - $67.26 $336,081 - $421,652	6,269 New	6,269 $363,000

Others Institutions Holding ALKS

# of Institutions

361

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Account

Verition Fund Management LLC Alkermes Plc. Transaction History